Amplia eyes major role in new cancer drug frontier
Amplia Therapeutics is positioning its “shield-breaker” cancer drug as a key partner for a new class of kRAS inhibitors, a major theme at a recent global oncology conference.
Amplia Therapeutics is positioning its “shield-breaker” cancer drug as a key partner for a new class of kRAS inhibitors, a major theme at a recent global oncology conference.